GlassScriptPhysician profile
Cara C Bondly
NPI 1588637250
$17,117.59
in general payments reported to CMS, 2019-2025
78 companies · $3,243 in 2025
The $3,243 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $2,323 · 2021: $2,356 · 2022: $2,253 · 2023: $2,313 · 2024: $3,191 · 2025: $3,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,342 · Long Term Medical Supply Or Device Loan: $1,296 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,341.88 |
| Long Term Medical Supply Or Device Loan | $1,296.10 |
| Education | $108.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,963.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $942.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Octapharma USA, INC. | $842.62 | 2020 | |
| Janssen Biotech, INC. | $774.24 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $740.50 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $702.23 | 2020-2025 | Opdivo, Opdualag |
| Amgen INC. | $664.31 | 2019-2023 | Blincyto |
| Celgene Corporation | $650.29 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $594.23 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Abbvie INC. | $482.66 | 2023-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $461.88 | 2019-2025 | Somatuline Depot, Onivyde |
| Daiichi Sankyo INC. | $423.59 | 2020-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $420.29 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Incyte Corporation | $411.09 | 2020-2025 | Pemazyre, Monjuvi, Jakafi |
| Pfizer INC. | $350.04 | 2019-2024 |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $318.69 | 2021-2025 | |
| Eisai INC. | $280.52 | 2019-2025 | |
| Genentech USA, INC. | $268.45 | 2019-2025 | Lunsumio, Columvi, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $266.77 | 2019-2023 | Imbruvica, Epkinly |
| Deciphera Pharmaceuticals INC. | $240.34 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Alexion Pharmaceuticals, INC. | $180.42 | 2020-2024 | Soliris, Ultomiris |
| Glaxosmithkline, LLC. | $178.52 | 2019-2025 | Jemperli, Zejula, Ojjaara |
| Sobi, INC | $177.34 | 2022-2025 | |
| Beigene USA, INC. | $176.82 | 2020-2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $174.82 | 2019-2025 | |
| Stemline Therapeutics INC. | $170.82 | 2023-2025 | Orserdu |
| Gilead Sciences, INC. | $165.96 | 2021-2025 | Trodelvy |
| Tesaro, INC. | $144.29 | 2019 | |
| Springworks Therapeutics, INC. | $135.64 | 2024-2025 | Ogsiveo |
| Exelixis INC. | $124.58 | 2019-2024 | Cabometyx |
| Taiho Oncology, INC. | $119.18 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $118.48 | 2021-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $116.01 | 2020-2022 | |
| Beone Medicines USA, INC. | $103.11 | 2025 | Brukinsa, Tevimbra |
| Kite Pharma, INC. | $102.29 | 2021-2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $99.11 | 2021-2022 | |
| Lilly USA, LLC | $88.97 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Pharmaessentia USA Corporation | $88.63 | 2023-2025 | Besremi |
| Jazz Pharmaceuticals INC. | $87.00 | 2021-2025 | |
| Puma Biotechnology, INC. | $81.39 | 2020-2024 | Nerlynx |
| Astellas Pharma US INC | $77.58 | 2020-2025 | Vyloy, Padcev |
| Aveo Pharmaceuticals, INC. | $75.90 | 2021-2024 | |
| Rigel Pharmaceuticals, INC. | $75.62 | 2020-2024 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.63 | 2020-2024 | Gilotrif |
| Blueprint Medicines Corporation | $72.24 | 2021-2024 | Ayvakit |
| Epizyme, INC. | $71.22 | 2021 | |
| Array Biopharma INC | $71.02 | 2019-2025 | Tukysa, Braftovi, Mektovi |
| Iovance Biotherapeutics, INC. | $67.85 | 2024-2025 | Amtagvi |
| Regeneron Healthcare Solutions, INC. | $61.13 | 2023-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $60.49 | 2023-2025 | Orgovyx |
| Janssen Pharmaceuticals, INC | $59.23 | 2019-2021 | |
| Dova Pharmaceuticals | $57.95 | 2019-2020 | |
| Adc Therapeutics America, INC. | $57.71 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $54.32 | 2025 | |
| Recordati_rare_diseases_inc. | $52.13 | 2025 | Enjaymo, Sylvant |
| Spectrum Pharmaceuticals INC. | $52.04 | 2023-2025 | Rolvedon |
| Pharming Healthcare, INC. | $49.18 | 2023-2025 | Ruconest |
| Coherus Oncology, INC. | $44.71 | 2024-2025 | Loqtorzi |
| Acrotech Biopharma INC. | $41.76 | 2024 | Beleodaq |
| Agios Pharmaceuticals, INC. | $41.65 | 2023-2025 | Pyrukynd |
| Tersera Therapeutics LLC | $41.50 | 2021-2024 | Quzyttir |
| Csl Behring | $40.75 | 2022 | |
| Cti Biopharma Corp. | $36.93 | 2022-2023 | Vonjo |
| Eusa Pharma (US) LLC | $35.81 | 2022 | |
| Secura Bio, INC. | $34.86 | 2020 | |
| Myovant Sciences INC. | $32.91 | 2022 | |
| Mirati Therapeutics, INC. | $31.24 | 2023-2024 | Krazati |
| Helsinn Therapeutics (U.S.), INC. | $29.92 | 2021 | |
| Kyowa Kirin, INC. | $26.40 | 2019-2020 | |
| Clovis Oncology, INC. | $25.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.13 | 2023 | Empaveli |
| Morphosys, US INC. | $18.85 | 2023 | Monjuvi |
| Innate Pharma, INC | $17.76 | 2020 | |
| Aurobindo Pharma USA, INC. | $16.79 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2021 | |
| Fennec Pharmaceuticals, INC. | $15.97 | 2025 | Fyarro |
| Acceleron Pharma, INC. | $14.45 | 2021 | |
| Adaptive Biotechnologies Corporation | $13.90 | 2023 | Clonoseq |
Drugs and devices associated with these payments
Kisqali $1,695Keytruda $497Enhertu $313Venclexta $292Imbruvica $259Lynparza $236Reblozyl $216Ninlaro $197Qinlock $187Scemblix $185Pluvicto $173Orserdu $171Fruzaqla $164Sarclisa $157Brukinsa $153Monjuvi $149Tukysa $143Epkinly $138Ogsiveo $136Pemazyre $131Jakafi $129Calquence $121Somatuline Depot $111Onivyde $111Imfinzi $98.87Opdivo $95.71Pomalyst $91.52Besremi $88.63Fabhalta $87.42Vonjo $81.01Darzalex $80.63Jemperli $80.09Padcev $79.64Orgovyx $77.72Lunsumio $73.00Polivy $73.00Columvi $73.00Lutathera $70.29Elahere $69.25Amtagvi $67.85Welireg $65.94Lenvima $64.72Adcetris $61.65Libtayo $61.13Opdualag $60.31Tecentriq $59.39Enjaymo $57.94Cabometyx $57.94Romvimza $57.67Soliris $56.31Monoferric $52.20Rolvedon $52.04Mekinist $51.47Ayvakit $49.92Ruconest $49.18Tevimbra $49.04Yescarta $48.59Gamifant $46.32Tasigna $44.51Vitrakvi $44.39Stivarga $44.39Ibrance $42.92Zepzelca $42.91Beleodaq $41.76Pyrukynd $41.65Piqray $41.04Phesgo $39.65Doptelet $35.18Trodelvy $34.78Rybrevant $34.64Tecvayli $33.66Alunbrig $33.33Tgct $31.86Krazati $31.24Inqovi $31.10Lonsurf $31.10Itovebi $28.76Gilotrif $28.40Cablivi $27.55Nubeqa $26.88Bosulif $26.30Elrexfio $26.30Oxbryta $25.28Talvey $24.14Quzyttir $24.08Udenyca $23.81Fotivda $23.58Tafinlar $23.26Mektovi $23.07Braftovi $23.07Ultomiris $22.72Nerlynx $22.47Sylvant $21.74Promacta $21.55Voranigo $21.14Loqtorzi $20.90Zynlonta $20.87Vyloy $20.72Blincyto $19.83Empaveli $19.13
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Bondly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.